Recurrence Rate for Isolated Elevated Maternal Serum Alpha-Fetoprotein Levels and Pregnancy Outcomes
Recommended Citation
Ayyash M, Keerthy M, Roberson J, and Shaman M. Recurrence Rate for Isolated Elevated Maternal Serum Alpha-Fetoprotein Levels and Pregnancy Outcomes. Genet Test Mol Biomarkers 2022; 26(9):443-448.
Document Type
Article
Publication Date
9-1-2022
Publication Title
Genet Test Mol Biomarkers
Abstract
Objective: To examine the rate of recurrence for elevated isolated maternal serum alpha-fetoprotein (MSAFP) and its associated adverse outcomes during a subsequent pregnancy.
Materials and Methods: A retrospective cohort study of pregnant multiparous women who had elevated MSAFP levels during an initial and a subsequent pregnancy between 1994 and 2020.
Results: Twenty-seven out of 344 (7.8%) women with elevated MSAFP had recurrent elevated MSAFP in a subsequent pregnancy. Four women were excluded due to missing data. Of the 23 women included, 5 (22%) had fetal growth restriction (FGR), 2 (9%) had pre-eclampsia, 9 (35%) had preterm births, and 2 (9%) had fetal death/miscarriage in their subsequent pregnancy. Looking at individual outcomes, 60% of women had recurrence of preterm labor, 33% had recurrence of fetal death, and 25% had recurrence of FGR.
Conclusion: Women with elevated MSAFP levels during an initial pregnancy should be informed during preconception counseling about their risk of recurring elevated MSAFP and its associated adverse outcomes risks.
Medical Subject Headings
Female; Fetal Death; Fetal Growth Retardation; Humans; Infant, Newborn; Male; Pregnancy; Pregnancy Outcome; Retrospective Studies; alpha-Fetoproteins
PubMed ID
36166740
Volume
26
Issue
9
First Page
443
Last Page
448